Soft Tissue Infections Clinical Trials

A listing of Soft Tissue Infections medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

Chula Vista California 91911

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

La Mesa California 91942

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Oceanside California 92056

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Santa Ana California 92705

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Santa Ana California 92705

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

View More ▼

Stockton California 95204

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Connecticut

New Haven Connecticut 06520

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

District of Columbia

Washington District of Columbia 20010

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Florida

Miami Florida 33144

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

West Palm Beach Florida 33407

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Georgia

Augusta Georgia 30909

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Columbus Georgia 31904

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Indiana

Indianapolis Indiana 46202

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Kentucky

Lexington Kentucky 40536

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Louisiana

New Orleans Louisiana 70112

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Massachusetts

Boston Massachusetts 02114

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Boston Massachusetts 02115

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Springfield Massachusetts 01199

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Michigan

Detroit Michigan 48202

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Missouri

Columbia Missouri 65211

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Montana

Butte Montana 59701

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Nevada

Las Vegas Nevada 89119

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

New Jersey

Somers Point New Jersey 08244

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

North Carolina

Charlotte North Carolina 28208

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Ohio

Columbus Ohio 43210

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Dayton Ohio 45409

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Oklahoma

Oklahoma City Oklahoma 73104

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Pennsylvania

Bethlehem Pennsylvania 18015

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

South Dakota

Rapid City South Dakota 57702

A Phase 3 clinical study for patients with Bacterial Infections or Skin Structures and Soft Tissue Infections, ABSSSI (Eudra #2013-003644-23)

Texas

Dallas Texas 75390

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Fort Worth Texas 76104

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Houston Texas 77030

A Phase 4 clinical study for patients with Impetigo, Folliculitis, Secondarily Infected Eczema or Minor Soft Tissue Infections

Utah

Pharmaceutical Research Organization
Bountiful Utah 84010

A Study of the Flector® Patch in Pediatric Patients with Minor Soft Tissue Injuries.

Virginia

Richmond Virginia 23298

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Washington

Seattle Washington 98104

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Japan

UPDATED

Amagasaki Hyogo 660-8511

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Fukuoka 810-0001

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Gifu 500-8513

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Hamamatsu Shizuoka 430-0929

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Inashiki-gun Ibaraki 300-0395

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

View More ▼

UPDATED

Iwata Shizuoka 438-8550

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kamakura Kanagawa 247-8533

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kasuga Fukuoka 816-0864

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kitakyushu Fukuoka 802-0077

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kobe Hyogo 650-0017

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kochi 781-8555

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kofu Yamanashi 400-8506

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Koshi Kumamoto 861-1196

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Kumamoto 860-0008

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious

UPDATED

Meguro-ku Tokyo 152-8902

Patients are needed to participate in a clinical research study of Tedizolid(BAY1192631) and Linezolid to evaluate Skin Diseases, Infectious